



US00RE35886E

United States Patent

[19]

[11] E

Patent Number: Re. 35,886**Wakimasu et al.****[45] Reissued Date of Patent: Sep. 1, 1998**[54] **PHOSPHONIC ACID DERIVATIVES AND USE THEREOF**[75] Inventors: **Mitsuhiko Wakimasu**, Osaka; **Masaaki Mori**; **Akira Kawada**, both of Tsukuba, all of Japan[73] Assignee: **Takeda Chemical Industries, Ltd.**, Osaka, Japan[21] Appl. No.: **680,295**[22] Filed: **Jul. 12, 1996****Related U.S. Patent Documents**

Reissue of:

[64] Patent No.: **5,330,978**
Issued: **Jul. 19, 1994**
Appl. No.: **892,768**
Filed: **Jun. 3, 1992**[30] **Foreign Application Priority Data**Jun. 13, 1991 [JP] Japan 3-142099
Apr. 9, 1992 [JP] Japan 4-089111[51] **Int. Cl.⁶** **C07F 9/22**; A61K 33/42[52] **U.S. Cl.** **514/80**; 514/80; 514/118;
548/414; 558/171[58] **Field of Search** 548/414; 558/171;
514/80, 118[56] **References Cited****U.S. PATENT DOCUMENTS**4,379,146 4/1983 Greenlee et al. 424/177
4,432,972 2/1984 Karanewsky et al. 424/177**OTHER PUBLICATIONS**

Proc. Natl. Acad. Sci. USA—"Phosphorus-containing Inhibitors of Angiotensin-converting Enzyme", vol. 79, pp. 2176-2180, Apr. 1982.

Biochemistry, "Phosphoramidates as Transition-State analogue Inhibitors of Thermolysin", 22, 4618-4624, 1982.

Biochemical and Biophysical Res. Comm., "Inhibitions of Biological Actions of Big Endothelin-1 by Phosphoramidon" vol. 172, No. 2, pp. 390-395, 1990.

Grobelyny et al., "Binding Energetics of Phosphorus-containing Inhibitors of Thermolysin", Biochemistry, vol. 28, No. 12 pp. 4948-4951, 1989.

Wakimasu, Rule 132 Declaration, Paper #10, File Wrapper of U.S. Patent No. 5,330,978 (admissions).

Morgan et al., "Differential Binding Energy: A Detailed Evaluation of the Influence of Hydrogen-Bonding and Hydrophobic Groups on the Inhibition of Thermolysin by Phosphorus containing Inhibitors", Journal of the American Chemical Society, vol. 113, No. 1, 1991.

Kam et al., "Inhibition of Thermolysin and Carboxypeptidase A by Phosphoramidates", Biochemistry, vol. 18, No. 14, pp. 3032-3038, 1979.

Mookhtiar, K.A., et al., "Phosphoramidate Inhibitors of Human Neutrophil Collagenase", Biochemistry, vol. 26, No. 7 (1987) (pp. 1962-1965).

McMahon et al., "Phosphoramidon Blocks The Pressor Activity of Porcine Big Endothelin-1-(1-39) In Vivo and Conversion of Big Endothelin-1-(1-39), 2 Endothelin-1-(1-21) In Vitro", Proceedings National Academy of Science, vol. 88 (Feb. 1991), pp. 703-777.


Rich, H. David, "Peptidase Inhibitors" in Comprehensive Medicinal Chemistry The Rational Design, Mechanistic Study & Therapeutic Application of Chemical Compounds, vol. 2 (Pergamon Press PLC), pp. 391-496 (not continuous), 1990.

Carey, et al., "Reaction and Synthesis": Chapter 11 entitled Multistep Synthesis at pp. 539-553, Advanced Organic Chemistry, Second Ed. Part B (New York Plenum Press, 1983).

Merz, et al., "Free Perturbation Simulations of the Inhibition of Thermolysin: Prediction of the Free Energy of Binding of a New Inhibitor", J. Am. Chem. Soc., vol. 111, No. 15 (1989), pp. 5649-5658.

Primary Examiner—Johann Richter*Assistant Examiner*—Joseph Murray*Attorney, Agent, or Firm*—David G. Conlin; George W. Neuner[57] **ABSTRACT**

A phosphonic acid derivative compound represented by formula [I] or a pharmaceutically acceptable salt thereof:

wherein R₁, R₂ and R₃ each represent hydrocarbon groups which may be substituted, except cases in which (1) R₂ is unsubstituted methyl, (2) R₃ is an unsubstituted hydrocarbon group having 1 to 3 carbon atoms, and (3) R₁ is benzyloxycarbonylaminoethyl, R₂ is isobutyl and R₃ is isobutyl or phenylmethyl, which has endothelin-converting enzyme inhibiting activity and is useful as pharmaceutical drugs such as therapeutic agents for hypertension, cardiac or cerebral circulatory diseases and renal diseases.

This is a Reissue of a Patent which was the subject of a Reexamination Certificate No. B1 5,330,978, dated Jun. 18, 1996, Request No. 90/00400, Oct. 18, 1995.

36 Claims, No Drawings

PHOSPHONIC ACID DERIVATIVES AND USE THEREOF

Matter enclosed in heavy brackets [] appears in the original patent but forms no part of this reissue specification; matter printed in italics indicates the additions made by reissue.

BACKGROUND OF THE INVENTION

The present invention relates to novel phosphonic acid derivatives having endothelin-converting enzyme inhibiting activity, and is further directed to methods for producing the same and their use.


Endothelin is a vasoconstrictive peptide composed of 21 amino acid residues which was isolated from the culture supernatant of the endothelin cells of porcine aortas and whose structure was determined by Yanagisawa et al. [Yanagisawa et al., *Nature*, 332, 411-415 (1988)]. From the research on genes coding for endothelin, as the biosynthetic mechanism of endothelin, endothelin was deduced to be biosynthesized from an endothelin precursor through big endothelin (*ibid.*). The subsequent studies have revealed the presence of enzymes for converting big endothelin to endothelin (endothelin-converting enzymes) [Ikekawa et al., *Biochem. Biophys. Res. Commu.*, 171, 669-675 (1990); and Okada et al., *ibid.*, 171, 1192-1198 (1990)].

Endothelin has vasopressor activity, so that it is anticipated to be an intrinsic factor responsible for the control of circulatory systems and deduced to be related to hypertension, cardiac or cerebral circulatory diseases and renal diseases. Inhibitors for the endothelin-converting enzymes are potential therapeutic drugs for these diseases. At present, however, no endothelin-converting enzyme inhibiting substances other than phosphoramidon are reported.

SUMMARY OF THE INVENTION

As a result of intensive investigation, the present inventors created novel compounds of the present invention having endothelin-converting enzyme inhibiting activity.

According to the present invention, there is provided a phosphonic acid derivative compound represented by formula [I] or a pharmaceutically acceptable salt thereof:



wherein R₁, R₂ and R₃ each represent hydrocarbon groups which may be substituted, except cases in which (1) R₂ is unsubstituted methyl, (2) R₃ is an unsubstituted hydrocarbon group having 1 to 3 carbon atoms, and (3) R₁ is benzyloxycarbonylaminoethyl, R₂ is isobutyl and R₃ is isobutyl or phenylmethyl. The present invention further provides a method for producing the same and use thereof.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

When amino acids and peptides are indicated by abbreviations in this specification, they are based on the abbreviations adopted by the IUPAC-IUB Commission on Biochemical Nomenclature or commonly used in the art. Examples thereof are as follows:

Val: Valine

Nva: Norvaline

Leu: leucine

Ile: Isoleucine

Nle: Norleucine

Met: Methionine

Cha: Cyclohexylalanine

Phe: Phenylalanine

Trp: Tryptophan

Protective groups and reagents frequently used in this specification are indicated by the following abbreviations:

Boc: t-Butoxycarbonyl

Bzl: Benzyl

HONB: N-hydroxy-5-norbornene-2,3-dicarboximide

DCC: N,N'-dicyclohexylcarbodiimide

DCHA: N,N'-dicyclohexylamine

In the compound of the present invention represented by formula [I], R₁, R₂ and R₃ each represent hydrocarbon groups which may be substituted, except cases in which (1) R₂ is unsubstituted methyl, (2) R₃ is an unsubstituted hydrocarbon group having 1 to 3 carbon atoms, and (3) R₁ is benzyloxycarbonylaminoethyl, R₂ is isobutyl and R₃ is isobutyl or phenylmethyl.

As the above-mentioned hydrocarbon group represented by R₁, an alkyl group, a cycloalkyl group or an aralkyl group is preferred. As the alkyl group, a straight chain or branched chain alkyl group having 1 to 12 carbon atoms is preferred. Examples thereof include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isoamyl, tert-amyl, n-hexyl, n-octyl, n-decyl and n-dodecyl. These alkyl groups may be substituted. The substituent groups include cycloalkyl such as cyclopropyl, cyclopentyl, cyclohexyl and cycloheptyl; halogen such as fluoro, chloro and bromo; hydroxy which may be protected; alkoxy such as methoxy and ethoxy; ketone, amino which may be protected; and substituted amino. The substituted alkyl groups include, for example, cyclohexylmethyl, 2-cyclohexylethyl, 2-fluoroethyl, 2-chloroethyl, 3-chloropropyl, 2-hydroxyethyl, 2-methoxyethyl and 2-aminoethyl. As the cycloalkyl group, a 5-, 6- or 7-membered alicyclic alkyl group is preferred. Examples thereof include cyclopentyl, cyclohexyl and cycloheptyl. These cycloalkyl groups may be substituted. The substituent groups include lower alkyl such as methyl, ethyl and n-propyl; halogen such as fluoro, chloro and bromo; hydroxy which may be protected; alkoxy such as methoxy and ethoxy; ketone, amino which may be protected; and substituted amino which may be protected. The substituted cycloalkyl groups include, for example, 4-methylcyclohexyl, 4-chlorocyclohexyl, 4-hydroxycyclohexyl and 4-methoxycyclohexyl. As the aralkyl group, an alkyl group having 1 to 5 carbon atoms substituted by an aromatic hydrocarbon group having 6 to 12 carbon atoms is preferred. Examples thereof include phenylmethyl (benzyl), 2-phenylethyl (phenethyl), 1-naphthylmethyl, 2-naphthylmethyl, 2-(1-naphthyl)ethyl, 2-(2-naphthyl)ethyl and 3-phenylpropyl. These aralkyl groups may be substituted. The substituent groups include lower alkyl such as methyl, ethyl and n-propyl; cycloalkyl such as cyclopentyl and cyclohexyl; halogen such as fluoro, chloro and bromo; hydroxy which may be protected; and alkoxy such as methoxy and ethoxy. The substituted aralkyl groups include, for example, 4-methylphenylmethyl, 2-(4-methylphenyl)ethyl, 4-fluorophenylmethyl, 2-(4-chlorophenyl)ethyl and 2-(4-methoxyphenyl)ethyl. Preferred examples of R₁ include isoamyl, cyclohexylmethyl, 2-phenylethyl, 1-naphthylmethyl, 2-naphthylmethyl, 2-(1-naphthyl)ethyl and 2-(2-naphthyl)ethyl.

As the above-mentioned hydrocarbon group represented by R_2 , an alkyl group, a cycloalkyl group or an aralkyl group is preferred. As the alkyl group, a straight chain or branched chain alkyl group having 1 to 8 carbon atoms is preferred. Examples thereof include methyl (except unsubstituted methyl), ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isoamyl, tert-amyl, n-hexyl and n-octyl. These lower alkyl groups may be substituted. The substituent groups include cycloalkyl such as cyclopentyl, cyclohexyl and cycloheptyl; halogen such as fluoro, chloro and bromo; hydroxy which may be protected; mercapto which may be protected; alkoxy such as methoxy and ethoxy; alkylthio such as methylthio and ethylthio; amino which may be protected; substituted amino which may be protected; guanidino which may be protected; carboxyl which may be protected; carbamoyl; ketone; and heterocyclic groups, wherein heterocyclic groups mean groups obtained by eliminating hydrogen atoms bound to carbon atoms of monocyclic to tricyclic heterocycles containing 1 to 3 nitrogen atoms and/or oxygen atoms and/or sulfur atoms as ring constituent atoms other than carbon atoms, for example, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyridazinyl, 3-furyl, 3-thienyl, 2-indolyl, 3-indolyl, 4-thiazolyl, 4-imidazolyl, benzofuryl and benzothienyl. The substituted lower alkyl groups include, for example, cyclohexylmethyl, 2-cyclohexylethyl, 2-fluoroethyl, 2-chloroethyl, 3-chloropropyl, hydroxymethyl, 2-hydroxyethyl, 2-methoxyethyl, 2-aminoethyl, 4-aminobutyl, 3-guanidinopropyl, carbamoylmethyl, 2-carbamoylethyl, mercaptomethyl, carboxymethyl, 2-carboxyethyl, 4-imidazolylmethyl and 3-indolylmethyl. As the cycloalkyl group, a 5-, 6 or 7-membered alicyclic alkyl group is preferred. Examples thereof include cyclopentyl, cyclohexyl and cycloheptyl. These cycloalkyl groups may be substituted. The substituent groups include lower alkyl such as methyl, ethyl and n-propyl; halogen such as fluoro, chloro and bromo; hydroxy which may be protected; and alkoxy such as methoxy and ethoxy. The substituted cycloalkyl groups include, for example, 4-methylcyclohexyl, 4-chlorocyclohexyl, 4-hydroxycyclohexyl and 4-methoxycyclohexyl. As the aralkyl group, an alkyl group having 1 to 5 carbon atoms substituted by an aromatic hydrocarbon group having 6 to 12 carbon atoms is preferred. Examples thereof include phenylmethyl, 1-naphthylmethyl, 2-phenylethyl, 2-naphthylmethyl, 2-(1-naphthyl)ethyl, 2-(2-naphthyl)ethyl and 3-phenylpropyl. These aralkyl groups may be substituted. The substituent groups include lower alkyl such as methyl, ethyl and n-propyl; cycloalkyl such as cyclopentyl, cyclohexyl and cycloheptyl; halogen such as fluoro, chloro and bromo; hydroxy which may be protected; and alkoxy such as methoxy and ethoxy. The substituted aralkyl groups include, for example, 4-methylphenylmethyl, 2-(4-methylphenyl)ethyl, 4-fluorophenylmethyl, 2-(4-chlorophenyl)ethyl and 2-(4-methoxyphenyl)ethyl. Preferred examples of R_2 include n-propyl, isopropyl, isobutyl, sec-butyl, cyclohexylmethyl and benzyl, and isobutyl is particularly preferred among others.

As the above-mentioned hydrocarbon group represented by R_3 , an alkyl group, a cycloalkyl group or an aralkyl group is preferred. As the alkyl group, a straight chain or branched chain unsubstituted alkyl group having 4 to 8 carbon atoms or a substituted alkyl group having 1 to 8 carbon atoms is preferred. Examples of the unsubstituted alkyl groups having 4 to 8 carbon atoms include n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isoamyl, tert-amyl, n-hexyl, isohexyl, n-heptyl and n-octyl. The substituent groups of the alkyl groups having 1 to 8 carbon atoms such as methyl, ethyl,

n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isoamyl, tert-amyl, n-hexyl, isohexyl, n-heptyl and n-octyl, include cycloalkyl such as cyclopentyl, cyclohexyl and cycloheptyl; halogen such as fluoro, chloro and bromo; hydroxy which may be protected; mercapto which may be protected; alkoxy such as methoxy and ethoxy, alkylthio such as methylthio and ethylthio; amino which may be protected; substituted amino which may be protected; guanidino which may be protected; carboxyl which may be protected; carbamoyl; ketone; and heterocyclic groups, wherein heterocyclic groups mean groups obtained by eliminating hydrogen atoms bound to carbon atoms of monocyclic to tricyclic heterocycles containing 1 to 3 nitrogen atoms and/or oxygen atoms and/or sulfur atoms as ring constituent atoms other than carbon atoms, for example, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyridazinyl, 3-furyl, 3-thienyl, 2-indolyl, 3-indolyl, 4-thiazolyl, 4-imidazolyl, benzofuryl and benzothienyl. The substituted alkyl groups include, for example, cyclohexylmethyl, 2-cyclohexylethyl, 2-fluoroethyl, 2-chloroethyl, 3-chloropropyl, hydroxymethyl, 2-hydroxyethyl, 2-methoxyethyl, 2-aminoethyl, 4-aminobutyl, 3-guanidinopropyl, carbamoylmethyl, 2-carbamoylethyl, mercaptomethyl, carboxymethyl, 2-carboxyethyl, 4-imidazolylmethyl and 3-indolylmethyl. As the cycloalkyl group, a 5-, 6- or 7-membered alicyclic alkyl group is preferred. Examples thereof include cyclopentyl, cyclohexyl and cycloheptyl. These cycloalkyl groups may be substituted. The substituent groups include lower alkyl such as methyl, ethyl and n-propyl; halogen such as fluoro, chloro and bromo; hydroxy which may be protected; and alkoxy such as methoxy and ethoxy. The substituted cycloalkyl groups include, for example, 4-methylcyclohexyl, 4-chlorocyclohexyl and 4-hydroxycyclohexyl. As the aralkyl group, an alkyl group having 1 to 5 carbon atoms substituted by an aromatic hydrocarbon group having 6 to 12 carbon atoms is preferred. Examples thereof include phenylmethyl, 2-phenylethyl, 2-naphthylmethyl, 2-(1-naphthyl)ethyl, 2-(2-naphthyl)ethyl and 3-phenylpropyl. These aralkyl groups may be substituted. The substituent groups include lower alkyl such as methyl, ethyl and n-propyl; cycloalkyl such as cyclopropyl, cyclopentyl, cyclohexyl and cycloheptyl; halogen such as fluoro, chloro and bromo; hydroxy which may be protected; and alkoxy such as methoxy and ethoxy. The substituted aralkyl groups include, for example, 4-methylphenylmethyl, 2-(4-methylphenyl)ethyl, 4-fluorophenylmethyl, 2-(4-chlorophenyl)ethyl and 2-(4-methoxyphenyl)ethyl. Preferred examples of R_3 include 3-indolylmethyl which may be substituted.

The carbon atoms of the compound of the present invention represented by formula [I] to which R_2 and R_3 are bound are all asymmetric carbon atoms. In the present invention, these carbon atoms include all the L-, the D- and the racemic forms.

The compounds of the present invention include a compound having formula [IV] or a pharmaceutically acceptable salt thereof:



where R_1 is as defined previously for Compound [I] and U and V are amino acid residues connected to the P-atom at the N-terminus and selected independently from substituted or unsubstituted amino acid residues with the proviso that (1) U is not a residue of Ala, (2) V is not a residue of Ala or Val

5

and (3) when R_1 is benzyloxycarbonylaminoethyl and U is a residue of Ile, V is not a residue of Ile or Phe. Preferred amino acid residues for compounds of the invention are derived from the twenty common amino acids found in proteins. Substituted amino acid residues in accord with the present invention contain substitutions as defined hereinabove with respect to R_1 , R_2 and R_3 . Such substituent hydrocarbon groups may also be used as substitutions for amino acid residues of formula IV.


The compounds of the present invention include salts of the compound represented by formula [I]. Such salts preferably include an ammonium salt, alkali metal salts such as a sodium salt and a potassium salt; alkaline earth metal salts such as a calcium salt and a magnesium salt; and organic base salts such as a pyridine salt and a triethylamine salt. Most preferably, the salts are pharmaceutically acceptable salts or salts that can be converted to pharmaceutically acceptable salts.

The compound of the present invention represented by formula [I], hereinafter occasionally referred to as compound [I] can be produced, for example, in the following manner. Namely, an organic phosphorus compound represented by formula [II], hereinafter occasionally referred to as compound [II] is reacted with a dipeptide compound represented by formula [III], hereinafter occasionally referred to as compound [III], or a salt thereof to prepare a phosphonic acid compound:



wherein A represents a protected hydroxyl group; X represents a halogen atom; Y represents a protected carboxyl group; and R_1' , R_2' and R_3' each represent hydrocarbon groups which may be substituted (for example, the groups listed hereinabove for R_1 , R_2 and R_3 , respectively), the hydrocarbon groups being protected with protecting groups if they have groups required to be protected, except cases in which (1) R_2' is unsubstituted methyl, (2) R_3' is an unsubstituted hydrocarbon group having 1 to 3 carbon atoms, and (3) R_1' is benzyloxycarbonylaminoethyl, R_2' is isobutyl and R_3' is isobutyl or phenylmethyl.

The resulting phosphonic acid compound is represented by formula [I] and hereinafter occasionally referred to as compound [I]:



wherein A, Y, R_1' , R_2' and R_3' have the meanings given above.

This compound is subjected to treatment for eliminating the protecting groups to obtain compound [I]. In some cases, the protecting groups are eliminated concurrently with the reaction of phosphorus compound [II] with dipeptide compound [III] or the salt thereof, whereby compound [I] can be obtained without treatment for eliminating the protecting groups.

"A" of organic phosphorus compound [II] is the protected hydroxyl group. As the protecting group, a known protecting group for P-OH is used. Specifically preferred such protecting groups include benzyl and 4-methylbenzyl. "X" of

6

organic phosphorus compound [II] is halogen, for example, chloro, bromo or iodo. "Y" of dipeptide compound [III] is the protected carboxyl group. As the protecting group, a known protecting group for a carboxyl group is used. Specifically preferred such protecting groups include benzyl and 4-methylbenzyl. The salt of dipeptide compound [III] preferably means a salt at the terminal amino group. Such salts include salts with inorganic acids such as hydrochloric acid and sulfuric acid; and salts with organic acids such as acetic acid and p-toluenesulfonic acid.

Described in more detail, this method comprises reacting organic phosphorus compound [II] with dipeptide compound [III] in an organic solvent, followed by treatment for eliminating the protecting groups to obtain the desired compound [I]. It is generally preferred to isolate the first reaction product, i.e. resulting phosphonic acid compound [I], before removing the protecting groups.

The organic solvent is selected from organic solvents which do not react with compounds [II] and [III]. Organic solvents preferably used are ether solvents such as tetrahydrofuran and dioxane, and halogenated hydrocarbon solvents such as dichloromethane and dichloroethane. Dichloromethane is most suitable among others. These solvents are preferably used in the anhydrous state. The amount of the organic solvent is usually about 10 to 100 ml/mmol of compound [III] and more preferably about 30 to 50 ml/mmol. Compound [II] is usually used in the same amount as that of compound [III] or in excess, specifically in an amount of 1 to 2.5 mmol/mmol of compound [III] and preferably in an amount of 1 to 1.5 mmol/mmol. The reaction of compound [II] with compound [III] is dehydrohalogenation reaction.

Bases are preferably used to eliminate hydrogen halides. Such bases used include inorganic bases such as sodium hydroxide and potassium hydroxide; and organic bases such as triethylamine and N-methylmorpholine; and the organic bases are more preferable among others. The bases are used in an amount enough to neutralize the hydrogen halides and the salts of compound [III], or in an amount of more than that. In some cases, liquid organic bases such as pyridine are used partly for solvents.

The reaction is conducted under cooling or at room temperature, usually at a temperature of about 0° to 25° C. The reaction time is usually 0.5 to 2 hours, though it varies depending on the kind of starting compound and the reaction temperature. After reaction, compound [I] can be isolated from the reaction solutions by combinations of known purifying techniques such as solvent extraction, distillation, column chromatography, liquid chromatography and recrystallization.

Protecting group eliminating reagents may be further added to the reaction solutions containing compound [I] to produce the desired compound [I]. The protecting groups of compound [I] can be eliminated using known protecting group eliminating reagents, according to known methods, although they may vary depending on the kind of protecting groups as is well known to those skilled in the art. After treatment for elimination of the protecting groups, compound [I] can be isolated from the reaction solutions by combinations of known purifying techniques such as solvent extraction, distillation, column chromatography, liquid chromatography and recrystallization. As a matter of course, treatment for isolation of compound [I] prior to eliminating the protecting groups typically makes purification of the desired compound [I] easier than without isolation of compound [I].

Compounds [II] and [III] used as starting compounds are commercially available or can be produced by or in accordance with methods known in the art.

Compound [I] of the present invention, including the pharmaceutically acceptable salts thereof, are useful as pharmaceutical drugs such as therapeutic agents for hypertension, cardiac or cerebral circulatory diseases and renal diseases. The pharmaceutically acceptable salts include, for example, an ammonium salt; alkali metal salts such as a sodium salt and a potassium salt; alkaline earth metal salts such as a calcium salt and a magnesium salt; and organic base salts such as a pyridine salt and a triethylamine salt. As these therapeutic agents, compound [I] can be administered in a treatment effective amount orally or parenterally in the form of a liquid formulation or a solid formulation to mammals such as humans, rabbits, dogs, cats, rats and mice. Usually, it is administered parenterally in the form of a liquid formulation, such as an injection. The dosage varies depending on the type of disease to be treated, the symptoms of the disease, the object to which the drug is given and the route of administration. For example, when parenterally given to human adult for treatment of hypertension, it is advantageous that compound [I] is given in the form of an injection by intravenous injection in one dose of about 0.01 to 20 mg/kg of weight, preferably about 0.05 to 10 mg/kg about once to 3 times a day. In the case of other routes and forms of administration, compound [I] can also be given in a dose similar thereto. The injections include subcutaneous injections, intracutaneous injections, intramuscular injections and drip injections, as well as intravenous injections. Such injections are prepared by methods known per se in the art, namely by dissolving, suspending and emulsifying compound [I] in sterile aqueous solutions or oily solutions. The aqueous solutions for injection include physiological saline and isotonic solutions containing glucose or other adjuvants, and may be used in combination with appropriate solubilizers such as alcohols, e.g. ethanol; polyalcohols, e.g. propylene glycol and polyethylene glycol; and nonionic surface active agents, e.g. Polysolvate 80 and HCO-50. The oily solutions include sesame oil and soybean oil, and may be used in combination with solubilizers such as benzyl benzoate and benzyl alcohol. The injections thus prepared are usually packed in appropriate capsules. Conveniently, compound [I] is packaged in a unit dose in a pharmaceutically acceptable carrier in a capsule or tablet form, or in a vial. The unit dose contains an amount of compound [I], as set forth above, for one administration to a patient. Typically, the unit dose will contain from about 0.5 to about 1500 mg, preferably about 2.5 to about 750 mg, of compound [I]. Vials can also conveniently be packaged for multiple doses for treatment for a prescribed period of time.

Compound [I] of the present invention has endothelin-converting enzyme inhibiting activity as shown by the procedures described in the Test Example. Endothelin is a peptide having vasoconstrictive activity, and therefore compound [I] is useful as pharmaceutical drugs such as therapeutic agents for hypertension, cardiac or cerebral circulatory diseases and renal diseases.

The present invention will be described in more detail with the following test example, reference example and examples. It is understood of course that these test example, reference example and examples are not intended to limit the scope of the invention. In the examples, all amino acids other than glycine take the L-form unless otherwise specified. In the examples, silica gel 60F-254 (Merck) was used as plates of thin layer chromatography, and Rf¹: chloroform-methanol (9:1) and Rf²: isopropanol-water-concentrated aqueous ammonia (5:2:0.2) were used as developing solvents.

TEST EXAMPLE

Measurement of Endothelin-Converting Enzyme Inhibiting Activity of Phosphonic Acid Amide Derivatives

In 1.5-ml centrifugal tube (BIO-BIK), 80 μ l of 50 mM bis-Trispropane-hydrochloric acid buffer (pH 7.2) supplemented with 1.0 mg/ml bovine serum albumin, 0.1M sodium chloride, 1.0 mM phenylmethanesulfonyl fluoride (PMSF, Wako Pure Chemical Industries), 1.0 μ g/ml leupeptin (Peptide Institute Inc.), 1.0 μ g/ml chymostatin (Peptide Institute Inc.), 1.0 μ g/ml pepstatin A (Peptide Institute Inc.), 1.0 μ M E-64 (Peptide Institute Inc.), 1.0 μ M thiorphan (Sigma) and 1.0 μ M angiotensin-converting enzyme inhibitor [CV-5975, Inada et al., Japanese Journal of Pharmacology, 47, 135-141 (1988)], 5 μ l of a sample solution to be tested (an aqueous solution or an aqueous solution containing 2% dimethyl sulfoxide) or 5 μ l of distilled water for the control plot, and 10 μ l of an endothelin-converting enzyme sample prepared as described in the following reference example were placed. After standing at 37° C. for 30 minutes, 5 μ l of a substrate solution [physiological phosphate buffer (PBS, containing 0.2 g of potassium chloride, 0.2 g of potassium dihydrogenphosphate, 8.0 g of sodium chloride and 1.14 g of disodium hydrogenphosphate in 1,000 ml of distilled water) supplemented with 1.0×10^{-6} M pig big endothelin I (1-39) (Peptide Institute Inc.) and 1.0 mg/ml bovine serum albumin] was added thereto to initiate enzyme reaction. After reaction at 37° C. for 1 hour, the reaction mixture was boiled in boiling water for 5 minutes, thereby terminating the reaction: The resulting insoluble material was removed by centrifugation, and endothelin I (1-21) produced by the enzyme reaction contained in 10 μ l of the supernatant was quantified by the endothelin I-specific sandwich enzyme immunoassay method already established [Suzuki et al., J. Immuno. Meth., 188, 245-250 (1989)], and compared with the amount of endothelin produced in the control plot to evaluate the enzyme inhibiting activity. The endothelin-converting enzyme inhibiting activity of the phosphonic acid derivatives of the present invention is shown in the following table. The inhibiting activity is indicated by the concentration of inhibitors required to provide 50% inhibition based on the amount converted to endothelin I in the control plot, namely the 50% inhibition concentration (IC50).

Inhibiting Activity of Phosphonic Acid Derivatives of the Present Invention on Endothelin-Converting Enzyme

Compound	IC50 (μ M)
N-(Phenethylphosphonyl)-Leu-Trp.2Na	0.2
N-(Isoamylphosphonyl)-Leu-Trp.2Na	0.7
N-(Cyclohexylmethylphosphonyl)-Leu-Trp.2Na	0.4
N-(Phenethylphosphonyl)-Phe-Trp.Na	0.5
N-(Phenethylphosphonyl)-Ile-Trp.2Na	1.2
N-(Phenethylphosphonyl)-Val-Trp.2Na	2.8
N-(Phenethylphosphonyl)-Cha-Trp.2Na	1.0
N-(Phenethylphosphonyl)-Nle-Trp.2Na	1.4
N-(Phenethylphosphonyl)-Leu-Phe.2Na	5.7
N-(Phenethylphosphonyl)-Leu-Leu.2Na	4.8
N-(1-Naphthylmethylphosphonyl)-Leu-Trp.2Na	0.2
N-(2-Naphthylmethylphosphonyl)-Leu-Trp.2Na	1.0
N-[2-(1-Naphthyl)ethylphosphonyl]-Leu-Trp.2Na	0.4
N-[2-(2-Naphthyl)ethylphosphonyl]-Leu-Trp.2Na	0.1

REFERENCE EXAMPLE

- Preparation of Endothelin-Converting Enzyme Sample for Assaying Enzyme Inhibiting Activity
As endothelin-converting enzymes existing in organisms, two kinds of metalloenzymes different in enzymological

properties are generally known. One exists in the cytoplasm, and the other is membrane-bound. The latter is characterized by that it is inhibited with phosphoramidon known as an inhibitor for metalloproteases [Matsumura et al., FEBS Lett., 272, 166-170 (1990)]. The endothelin-converting enzyme in the present invention means the membrane-bound enzyme of these two kinds of enzymes.

One example of the preparation thereof is hereinafter described.

About 500 g of the pig lung (of one pig) was sliced and disrupted in 2.0 liter of PBS supplemented with 0.05% sodium azide, 1.0 mM dithiothreitol, 1.0 mM PMSF, 1.0 µg/ml leupeptin, 1.0 µg/ml chymostatin, 1.0 µg/ml pepstatin A and 1.0 µM E-64, and then homogenized (1 minute×5 times) by a Polytron mixer (KINEMATICA). The centrifuged supernatant (240×G, 5 minutes) was further centrifuged at 10,000×G for 15 minutes, and the resulting supernatant was subjected to ultracentrifuge (100,000×G, 90 minutes) to obtain membrane fraction as a precipitate. To this precipitate, 1.0% Triton X-100 was added to solubilize enzyme activity. The protein amount of the solubilized membrane fractions was about 2.3 g. This was diluted to 2.0 mg of protein/ml to use for assaying the activity of enzyme inhibitors.

2. Measurement of Molecular Weight of Endothelin-Converting Enzyme

2.0 ml of an enzyme solution obtained by treatment similar to that described above using 1.0% 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acid (CHAPS) in place of 1.0% Triton X-100 as the solubilizing agent was subjected to gel filtration using a HiLoad 16/60 Superdex 200 pg column (Pharmacia, 1.6×600 mm) pre-equilibrated with 50 mM Trihydrochloric acid buffer (pH 8.0) supplemented with 0.1% CHAPS, 0.15M sodium chloride, 0.02% sodium azide, 0.1 mM PMSF, 1.0 µg/ml leupeptin, 1.0 µg/ml pepstatin A and 1.0 µM E-64. The same buffer as used for equilibration was used as an elution, and the flow rate was 0.5 ml/minute. Separately taking 5.0 ml of each eluate, the endothelin-converting enzyme activity of each fraction was assayed. The molecular weight of this enzyme was estimated to be about 300,000 from a comparison between the elution position of the enzyme activity and that of the standard position for calibration of molecular weight analyzed under the same conditions. Chromatography was conducted using a BioPilot system (Pharmacia).

3. Various Properties of Endothelin-Converting Enzyme

3-1. Optimum Ph

Using bis-Tris-hydrochloric acid buffer, Tris-hydrochloric acid buffer or diethanolamine-hydrochloric acid buffer, the enzyme activity was assayed at various pHs. As a result, this enzyme has an optimum pH around pH 7.5

3-2. Behavior to Various Protease Inhibitors

The inhibiting ratio of various protease inhibitors to this enzyme is shown in the following table. This enzyme was not inhibited so much by a specific enzyme inhibitor to each of serine protease, SH protease and acid protease, and was inhibited by o-phenanthroline or ethylenediaminetetraacetic acid which is a metal chelating agent inhibiting the activity of metalloprotease, and by phosphoramidon known as a metalloprotease inhibitor. From the above, this enzyme was concluded to be a metalloenzyme. This enzyme was also inhibited by an SH reagent. A similar phenomenon is known to be observed in some kind of metalloprotease.

Inhibition Effect of Various Protease Inhibitors on Endothelin-Converting Enzyme

Inhibitor	Concentration (µM)	Inhibiting Ratio (%)
<u>Serine protease inhibitor</u>		
PMSF	1000	32
Leupeptin	100	23
Chymostatin	100	2
SH protease inhibitor E-64	100	9
SH reagent Dithiothreitol	1000	96
Acid protease inhibitor	100	20
Pepstatin		
<u>Metalloprotease inhibitor</u>		
o-Phenanthroline	1000	92
Ethylenediaminetetraacetic acid	1000	70
Phosphoramidone	100	70

3-3. Metal Requirement

Since this enzyme is a metalloenzyme, the metal requirement was examined. Various metals were added to the enzyme in the presence of o-phenanthroline to examine the restoration of its activity. As a result, this revealed that the activity of this enzyme was not restored by addition of copper (divalence), but restored by addition of any metal ions of manganese (divalence), zinc (divalence) and cobalt (divalence). This enzyme is therefore likely to contain any of these three kinds of metals at its active center.

3-4. Influence of Temperature

The activity of this enzyme at 37° C. is more than 3 times that at 25° C.

3-5. Kinetic Coefficient

The Michaelis coefficient of this enzyme to pig big endothelin was calculated to be about 5×10^{-6} M from the Lineweaver-Burk plot.

EXAMPLE 1

N-(Phenethylphosphonyl)-Leu-Trp.2Na

(1) Boc-Leu-Trp-OBzl

Trp-OBzl.HCl (purchased from Kokusan Kagaku) (8.39 g) was dissolved in N,N-dimethylformamide (200 ml), and triethylamine (3.90 ml) and Boc-Leu-ONB [prepared from Boc-Leu-OH.H₂O (6.32 g), HONB (4.77 g) and DCC (5.49 g)] were added thereto under ice cooling, followed by stirring for 12 hours. The solvent was removed by distillation under reduced pressure, and the residue was dissolved in ethyl acetate. The resulting solution was washed with water, 10% aqueous citric acid, water, saturated aqueous sodium hydrogencarbonate and water in this order. After drying with anhydrous sodium sulfate, the solvent was removed by distillation to obtain a crude product. Recrystallization from ethyl acetate-petroleum ether gave needle crystalline colorless Boc-Leu-Trp-OBzl (10.3 g).

Melting point: 131°-132° C., TLC R_f¹ 0.59

$[\alpha]_{25}^D = -23.8^\circ$ (C=1.04, MeOH)

elemental analysis: as C₂₉H₃₇N₃O₅ Calculated: C: 68.62; H: 7.35; N: 8.28. Found: C: 68.46; H: 7.53; N: 8.30.

(2) N-(O-Benzyl-P-Phenethylphosphonyl)-Leu-Trp-OBzl

1,2-Ethanedithiol (0.2 ml) and 8N hydrochloric acid-dioxane (20 ml) were added to Boc-Leu-Trp-OBzl (1.20 g) obtained in (1) under ice cooling to dissolve it, followed by stirring for 30 minutes. The solvent was removed by distillation under reduced pressure, and diethyl ether was added to the residue to precipitate crystals. The crystals were

filtered off, and dried. The resulting product was suspended in dichloromethane, and triethylamine (0.66 ml) and O-benzyl-P-phenethyl phosphochloridate [prepared from dibenzylphenethyl phosphonate (868 mg) and phosphorus pentachloride (544 mg) by the method described in E. D. Thorsett et al., Proc. Natl. Acad. Sci. USA, 79, 2176 (1982)] were added thereto under ice cooling, followed by stirring for 12 hours. Dichloromethane (50 ml) was added to the reaction solution for dilution, and then water was added thereto. After stirring for 10 minutes, the product was extracted with dichloromethane. The resulting dichloromethane solution was washed with 10% aqueous citric acid, water, saturated aqueous sodium hydrogencarbonate and water in this order. After drying with anhydrous sodium sulfate, the solvent was removed by distillation. The residue was purified by silica gel column chromatography. A crude product was obtained from fractions eluted with chloroform. Recrystallization from ethyl acetate-petroleum ether gave needle crystalline colorless N-(O-benzyl-P-phenethylphosphonyl)-Leu-Trp-bBzl (580 mg).

Melting point: 85°–87° C., TLC Rf¹ 0.31

Elemental analysis: as C₃₉H₄₄N₃O₅P Calculated: C: 70.36; H: 6.66; N: 6.31. Found: C: 70.10; H: 6.64; N: 6.23.

IR ν_{max}(KBr)cm⁻¹: 1740 (C=O), 1660 (NHC=O), 1560 (Ar), 1190 (P=O)

NMR δppm(CDCl₃): 0.81–0.88 (6H, m), 1.27–1.37 (1H, m), 1.50–1.56 (1H, m), 1.60–1.70 (1H, m), 1.78–1.91 (1H, m), 1.93–2.00 (1H, m), 2.72–2.93 (3H, m), 3.25–3.30 (2H, m), 3.73–3.88 (1H, m), 4.71–5.10 (5H, m), 6.75–7.90 (22H, m)

(3) N-(Phenethylphosphonyl)-Leu-Trp.2Na

N-(O-Benzyl-P-phenethylphosphonyl)-Leu-Trp-OBzl (70.0 mg) obtained in (2) and sodium hydrogencarbonate (7.7 mg) were dissolved in methanol-water (10:1) (11 ml), and 10% palladium-carbon (20 mg) was added thereto to conduct catalytic reduction in a stream of hydrogen at ordinary temperature at ordinary pressure for 1.5 hours. The catalyst was removed by filtration, and the filtrate was concentrated under reduced pressure, followed by addition of water. Lyophilization gave powdery N-(phenethylphosphonyl)-Leu-Trp.2Na (40.3 mg).

TLC Rf¹ 0.58

LSIMS: m/z=530.2 [M+H⁺]

EXAMPLE 2

N-(Phenethylphosphonyl)-Ile-Trp.2Na

(1) Boc-Ile-Trp-OBzl

Trp-OBzl.HCl (purchased from Kokusan Kagaku) (8.39 g) was condensed with BOC-Ile-ONB [prepared from Boc-Ile.4H.0.5H₂O (6.09 g), HONB (4.77 g) and DCC (5.49 g)] in a manner similar to that of Example 1-(1) to obtain needle crystalline colorless Boc-Ile-Trp-OBzl (8.02 g).

Melting point: 111°–112° C., TLC Rf¹ 0.56

[α]_D²⁵=−25.5° C. (C=1.05, MeOH)

Elemental analysis: as C₂₉H₃₇N₃O₅ Calculated: C: 68.62; H: 7.35; N: 8.28. Found: C: 68.50; H: 7.57; N: 8.23.

(2) N-(O-Benzyl-P-Phenethylphosphonyl)-Ile-Trp-OBzl

1,2-Ethanedithiol (0.2 ml) and 8N hydrochloric acid-dioxane (20 ml) were added to Boc-Ile-Trp-OBzl (1.62 g) obtained in (1) under ice cooling to dissolve it, followed by stirring for 30 minutes. The solvent was removed by distillation under reduced pressure, and diethyl ether was added to the residue to precipitate crystals. The crystals were filtered off, and dried. The resulting product was reacted with O-benzyl-P-phenethyl phosphochloridate [prepared from dibenzylphenethyl phosphonate (1.17 g) and phospho-

rus pentachloride (800 mg)] in a manner similar to that of Example 1-(2) to obtain needle crystalline colorless N-(O-benzyl-P-phenethylphosphonyl)-Ile-Trp-OBzl (390 mg).

Melting point: 151°–152° C., TLC Rf¹ 0.23

Elemental analysis: as C₃₉H₄₄N₃O₅P Calculated: C: 70.36; H: 6.66; N: 6.31. Found: C: 70.10; H: 6.64; N: 6.23.

IR ν_{max}(KBr)cm⁻¹: 1730 (C=O), 1660 (NHC=O), 1540 (Ar), 1200 (P=O)

NMR δppm(CDCl₃): 0.70–0.88 (6H, m), 0.93–1.03 (1H, m), 1.33–1.42 (1H, m), 1.63–1.76 (1H, m), 1.79–1.93 (1H, m), 1.93–2.02 (1H, m), 2.55–2.91 (2H, m), 2.94–3.02 (1H, m), 3.19–3.22 (2H, m), 3.59–3.67 (1H, m), 4.73–5.11 (5H, m), 6.51–7.87 (22H, m)

(3) N-(Phenethylphosphonyl)-Ile-Trp.2Na

N-(O-Benzyl-P-phenethylphosphonyl)-Ile-Trp-OBzl (70.0 mg) obtained in (2) was subjected to catalytic reduction in a manner similar to that of Example 1-(3) to obtain powdery N-(phenethylphosphonyl)-Ile-Trp.2Na (45.8 mg).

TLC Rf² 0.58

LSIMS: m/z=530.2 [M+H⁺]

EXAMPLE 3

25

N-(Phenethylphosphonyl)-Val-Trp.2Na

(1) Boc-Val-Trp-OBzl

Trp-OBzl.HCl (purchased from Kokusan Kagaku) (500 g) was condensed with Boc-Val-ONB [prepared from Boc-Val-OH (3.28 g), HONB (2.84 g) and DCC (3.27 g)] in a manner similar to that of Example 1-(1) to obtain needle crystalline colorless Boc-Val-Trp-OBzl (4.88 g).

Melting point: 139°–140° C., TLC Rf¹ 0.44

[α]_D²⁵=−21.8° C. (C=1.04, MeOH)

Elemental analysis: as C₂₈H₃₅N₃O₅ Calculated: C: 68.13; H: 7.15; N: 8.51. Found: C: 68.13; H: 7.08; N: 8.51.

(2) N-(O-Benzyl-P-Phenethylphosphonyl)-Val-Trp-OBzl

1,2-Ethanedithiol (0.2 ml) and 8N hydrochloric acid-dioxane (20 ml) were added to Boc-Val-Trp-OBzl (1.58 g) obtained in (1) under ice cooling to dissolve it, followed by stirring for 30 minutes. The solvent was removed by distillation under reduced pressure, and diethyl ether was added to the residue to precipitate crystals. The crystals were filtered off and dried. The resulting product was reacted with O-benzyl-P-phenethyl phosphochloridate [prepared from dibenzylphenethyl phosphonate (1.17 g) and phosphorus pentachloride (800 mg)] in a manner similar to that of Example 1-(2) to obtain needle crystalline colorless N-(O-benzyl-P-phenethylphosphonyl)-Val-Trp-OBzl (337 mg).

Melting point: 143°–144° C., TLC Rf¹ 0.23

Elemental analysis: as C₃₈H₄₂N₃O₅P.0.25H₂O Calculated: C: 69.55; H: 6.52; N: 6.40 Found: C: 69.53; H: 6.78; N: 6.31

IR ν_{max}(KBr)cm⁻¹: 1740 (C=O), 1660 (NHC=O), 1550 (Ar), 1200 (P=O)

NMR δppm(CDCl₃): 0.78–0.83 (3H, m), 0.87–0.92 (3H, m), 1.83–2.06 (3H, m), 2.76–2.93 (2H, m), 2.99–3.10 (1H, m), 3.19–3.32 (2H, m), 3.56–3.66 (1H, m), 4.22–5.60 (5H, m), 6.55–7.91 (22H, m)

(3) N-(Phenethylphosphonyl)-Val-Trp.2Na

N-(O-Benzyl-P-phenethylphosphonyl)-Val-Trp-OBzl (70.0 mg) obtained in (2) was subjected to catalytic reduction in a manner similar to that of Example 1-(3) to obtain powdery N-(phenethylphosphonyl)-Val-Trp.2Na (40.3 mg).

TLC Rf² 0.58

LSIMS: m/z=516.1 [M+H⁺]

65

13

EXAMPLE 4

N-(Phenethylphosphonyl)-Phe-Trp.2Na

(1) Boc-Phe-Trp-OBzl

Trp-OBzl.HCl (purchased from Kokusan Kagaku) (5.00 g) was condensed with Boc.-Phe-ONB [prepared from Boc-Phe-OH (4.01 g), HONB (2.84 g) and DCC (3.27 g)] in a manner similar to that of Example 1-(1) to obtain needle crystalline colorless Boc-Phe-Trp-OBzl (7.98 g).

Melting point: 129°–130° C., TLC Rf¹ 0.48

$[\alpha]_{25}^D = -4.1^\circ$ (C=1.04, MeOH)

Elemental analysis: as C₃₂H₃₅N₃O₅ Calculated: C: 70.96; H: 6.51; N: 7.76. Found: C: 70.70; H: 6.72; N: 7.53.

(2) N-(O-Benzyl-P-Phenethylphosphonyl)-Phe-Trp-OBzl

1,2-Ethanedithiol (0.2 ml) and 8N hydrochloric acid-dioxane (20 ml) were added to Boc-Phe-Trp-OBzl (1.73 g) obtained in (1) under ice cooling to dissolve it, followed by stirring for 30 minutes. The solvent was removed by distillation under reduced pressure, and diethyl ether was added to the residue to precipitate crystals. The crystals were filtered off and dried. The resulting product was reacted with O-benzyl-P-phenethyl phosphochloridate [prepared from dibenzylphenethyl phosphonate (1.17 g) and phosphorus pentachloride (800 mg)] in a manner similar to that of Example 1-(2) to obtain needle crystalline colorless N-(O-benzyl-P-phenethylphosphonyl)-Phe-Trp-OBzl (452 mg).

Melting point: 54°–55° C. TLC Rf¹ 0.30

Elemental analysis: as C₄₂H₄₂N₃O₅P Calculated: C: 72.09; H: 6.05; N: 6.00. Found: C: 69.71; H: 6.42; N: 5.75.

IR $\nu_{\max}(\text{KBr})\text{cm}^{-1}$: 1740 (C=O), 1660 (NHC=O), 1500 (Ar), 1200 (P=O)

NMR $\delta_{\text{ppm}}(\text{CDCl}_3)$: 1.45–1.68 (2H, m), 2.50–2.66 (2H, m), 2.72–3.03 (3H, m), 3.12–3.30 (2H, m), 4.01–4.15 (1H, m), 4.36–4.64 (1H, m), 4.75–4.83 (1H, m), 4.41–5.09 (3H, m), 6.60–7.87 (2H, m)

(3) N-(phenethylphosphonyl)-Phe-Trp.2Na

N-(O-Benzyl-p-phenethylphosphonyl)-Phe-Trp-OBzl (70 mg) obtained in (2) was subjected to catalytic reduction in a manner similar to that of Example 1-(3) to obtain powdery N-(phenethylphosphonyl)-Phe-Trp.2Na (45.0 mg).

TLC Rf² 0.58

LSIMS: m/z=564.1 [M+H⁺]

EXAMPLE 5

N-(phenethylphosphonyl)-Cha-Trp.2Na

(1) Boc-Cha-Trp-OBzl

Trp-OBzl.HCl (purchased from Kokusan Kagaku) (1.65 g) was condensed with Boc-Cha-ONB [prepared from Boc-Cha-OH.DCHA (purchased from Nova Biochem) (2.26 g), HONB (941 mg) and DCC (1.08 g)] in a manner similar to that of Example 1-(1) to obtain needle crystalline colorless Boc-Cha-Trp-OBzl (2.12 g).

Melting point: 67°–68° C., TLC Rf¹ 0.70

$[\alpha]_{25}^D = -14.9^\circ$ (C=1.02, MeOH)

Elemental analysis: as C₃₂H₄₁N₃O₅ Calculated: C: 70.18; H: 7.55; N: 7.67. Found: C: 70.23; H: 7.84; N: 7.38.

(2) N-(O-Benzyl-P-Phenethylphosphonyl)-Cha-Trp-OBzl

1,2-Ethanedithiol (0.2 ml) and 8N hydrochloric acid-dioxane (20 ml) were added to Boc-Cha-Trp-OBzl (1.75 g) obtained in (1) under ice cooling to dissolve it, followed by stirring for 30 minutes. The solvent was removed by distillation under reduced pressure, and diethyl ether was added to the residue to precipitate crystals. The crystals were filtered off and dried. The resulting product was reacted with O-benzyl-P-phenethyl phosphochloridate [prepared from

14

dibenzylphenethyl phosphonate (1.17 g) and phosphorus pentachloride (800 mg)] in a manner similar to that of Example 1-(2) to obtain needle crystalline colorless N-(O-benzyl-p-phenethylphosphonyl)-Cha-Trp-OBzl (410 mg).

Melting point: 107°–109° C., TLC Rf¹ 0.28

Elemental analysis: as C₄₂H₄₈N₃O₅P Calculated: C: 71.47; H: 6.85; N: 5.95. Found: C: 71.38; H: 6.93; N: 5.58.

IR $\nu_{\max}(\text{KBr})\text{cm}^{-1}$: 1750 (C=O), 1660 (NHC=O), 1500 (Ar), 1200 (P=O).

NMR $\delta_{\text{ppm}}(\text{CDCl}_3)$: 0.76–0.93 (2H, m), 1.04–1.21 (3H, m), 1.26–1.41 (2H, m), 1.53–1.73 (6H, m), 1.84–2.01 (2H, m), 2.71–2.91 (3H, m), 3.24–3.31 (2H, m), 3.78–3.87 (1H, m), 4.70–5.11 (5H, m), 6.71–7.96 (22H, m)

(3) N-(Phenethylphosphonyl)-Cha-Trp.2Na

N-(O-Benzyl-P-phenethylphosphonyl)-Cha-Trp-OBzl (70.6 mg) obtained in (2) was subjected to catalytic reduction in a manner similar to that of Example 1-(3) to obtain powdery N-(phenethylphosphonyl)-Val-Trp.2Na (38.4 mg).

TLC Rf² 0.58

LSIMS: m/z=570.2 [M+H⁺]

EXAMPLE 6

N-[phenethylphosphonyl]-Nle-Trp.2Na

(1) Boc-Nle-Trp-OBzl

Trp-OBzl.HCl (purchased from Kokusan Kagaku) (1.65 g) was condensed with Boc-Nle-ONB [prepared from Boc-Nle-OH.DCHA (purchased from Nova Biochem) (2.06 g), HONB (941 mg) and DCC (1.08 g)] in a manner similar to that of Example 1-(1) to obtain oily light yellow Boc-Nle-Trp-OBzl (2.41 g).

TLC Rf¹ 0.55

LSIMS: m/z=508.2 (M⁺)

IR $\nu_{\max}(\text{KBr})\text{cm}^{-1}$: 1680 (NHC=O), 1510 (Ar)

NMR $\delta_{\text{ppm}}(\text{CDCl}_3)$: 0.83 (3H, t), 1.18–1.31 (4H, m), 1.41 (9H, s), 1.65–1.80 (2H, m), 3.25–3.35 (2H, m), 4.04 (1H, broad, s), 4.40–4.99 (2H, m), 5.07 (2H, s), 6.50–6.55 (1H, m), 6.94–7.51 (10H, m), 8.13 (1H, broad, s)

(2) N-(O-Benzyl-P-Phenethylphosphonyl)-Nle-Trp-OBzl

1,2-Ethanedithiol (0.2 ml) and 8N hydrochloric acid-dioxane (20 ml) were added to Boc-Nle-Trp-OBzl (1.62 g) obtained in (1) under ice cooling to dissolve it, followed by stirring for 30 minutes. The solvent was removed by distillation under reduced pressure, and diethyl ether was added to the residue to precipitate crystals. The crystals were filtered off and dried. The resulting product was reacted with O-benzyl-P-phenethyl phosphochloridate prepared from dibenzylphenethyl phosphonate (1.17 g) and phosphorus pentachloride (800 mg)] in a manner similar to that of Example 1-(2) to obtain oily colorless N-(O-benzyl-P-phenethylphosphonyl)-Nle-Trp-OBzl (150 mg).

TLC Rf¹ 0.27

LSIMS: m/z=666.3 (M⁺)

IR $\nu_{\max}(\text{KBr})\text{cm}^{-1}$: 1740 (C=O), 1660 (NHC=O), 1500 (Ar), 1190 (P=O)

NMR $\delta_{\text{ppm}}(\text{CDCl}_3)$: 0.80–0.87 (3H, m), 1.16–1.28 (4H, m), 1.41–1.83 (2H, m), 1.83–2.01 (2H, m), 2.74–2.90 (3H, m), 3.25–3.30 (2H, m), 3.67–3.79 (1H, m), 4.73–5.13 (5H, m), 6.66–7.85 (22H, m)

(3) N-(Phenethylphosphonyl)-Nle-Trp.2Na

N-(O-Benzyl-P-phenethylphosphonyl)-Nle-Trp-OBzl (31.0 mg) obtained in (2) was subjected to catalytic reduction in a manner similar to that of Example 1-(3) to obtain powdery N-[phenethylphosphonyl]-Nle-Trp.2Na (13.3 mg).

TLC Rf² 0.58

LSIMS: m/z=530.2 [M+H⁺]

15

EXAMPLE 7

N-(Phenethylphosphonyl)-Leu-Phe.2Na

(1) Boc-Leu-Phe-OBzl

Phe-OBzl.Tos (purchased from Peptide Laboratory) (7.27 g) was condensed with Boc-Leu-ONB [prepared from Boc-Leu-OH.H₂O (3.93 g), HONB (3.20 mg) and DCC (3.68 g)] in a manner similar to that of Example 1-(1) to obtain needle crystalline colorless Boc-Leu-Phe-OBzl (5.64 g).

Melting point: 100°–101° C., TLC Rf¹ 0.66

$[\alpha]_{25}^D = -35.3^\circ$ (C=1.04, MeOH)

Elemental analysis: as C₂₇H₃₆N₂O₅ Calculated: C: 69.21; H: 7.74; N: 5.98. Found: C: 69.42; H: 7.70; N: 6.05.

(2) N-(O-Benzyl-P-Phenethylphosphonyl)-Leu-phe-OBzl

1,2-Ethanedithiol (0.2 ml) and 8N hydrochloric acid-dioxane (20 ml) were added to Boc-Leu-Phe-OBzl (1.50 g) obtained in (1) under ice cooling to dissolve it, followed by stirring for 30 minutes. The solvent was removed by distillation under reduced pressure, and diethyl ether was added to the residue to precipitate crystals. The crystals were filtered off and dried. The resulting product was reacted with O-benzyl-P-phenethyl phosphochloridate [prepared from dibenzylphenethyl phosphonate (1.17 g) and phosphorus pentachloride (800 mg)] in a manner similar to that of Example 1-(2) to obtain needle crystalline colorless N-(O-benzyl-P-phenethylphosphonyl)-Leu-Phe-OBzl (351 mg).

Melting point: 93°–95° C. TLC Rf¹ 0.37

Elemental analysis: as C₃₇H₄₃N₂O₅P Calculated: C: 70.91; H: 6.92; N: 4.47. Found: C: 70.64; H: 7.04; N: 4.30.

IR $\nu_{\max}(\text{KBr})\text{cm}^{-1}$: 1750 (C=O), 1660 (NHC=O), 1500 (Ar), 1190 (P=O)

NMR $\delta_{\text{ppm}}(\text{CDCl}_3)$: 0.85–0.90 (6H, m), 1.23–1.37 (1H, m), 1.48–1.56 (1H, m), 1.59–1.69 (1H, m), 1.92–2.06 (1H, m), 2.26–2.95 (3H, m), 3.01–3.13 (2H, m), 3.73–3.81 (1H, m), 4.87–5.16 (5H, m), 6.69–7.37 (21H, m)

(3) N-(Phenethylphosphonyl)-Leu-Phe.2Na

N-(O-Benzyl-P-phenethylphosphonyl)-Leu-Phe-OBzl (70.0 mg) obtained in (2) as subjected to catalytic reduction in a manner similar to that of Example 1-(3) to obtain powdery N-(phenethylphosphonyl)-Leu-Phe.2Na (52.4 mg).

TLC Rf² 0.58

LSIMS: $m/z=491.1$ [M+H⁺]

EXAMPLE 8

N-(Phenethylphosphonyl)-Leu-Leu.2Na

(1) Boc-Leu-Leu-OBzl

Leu-OBzl.Tos (purchased from Peptide Laboratory) (6.69 g) was condensed with Boc-Leu-ONB [prepared from Boc-Leu-OH.H₂O (3.93 g), HONB (3.20 mg) and DCC (3.68 g)] in a manner similar to that of Example 1-(1) to obtain needle crystalline colorless Boc-Leu-Leu-OBzl (5.67 g).

Melting point: 90°–91° C., TLC Rf¹ 0.94

$[\alpha]_{25}^D = -51.0^\circ$ (C=1.00, MeOH)

Elemental analysis: as C₂₄H₃₈N₂O₅ Calculated: C: 66.33; H: 8.81; N: 6.45. Found: C: 66.29; H: 8.78; N: 6.48.

(2) N-O-Benzyl-P-Phenethylphosphonyl)-Leu-Leu-OBzl

1,2-Ethanedithiol (0.2 ml) and 8N hydrochloric acid-dioxane (20 ml) were added to Boc-Leu-Leu-OBzl (1.39 g) obtained in (1) under ice cooling to dissolve it, followed by stirring for 30 minutes. The solvent was removed by distillation under reduced pressure, and diethyl ether was added to the residue to precipitate crystals. The crystals were filtered off and dried. The resulting product was reacted with O-benzyl-P-phenethyl phosphochloridate [prepared from

16

dibenzylphenethyl phosphonate (1.17 g) and phosphorus pentachloride (800 mg)] in a manner similar to that of Example 1-(2) to obtain needle crystalline colorless N-(O-benzyl-P-phenethylphosphonyl)-Leu-Leu-OBzl (385 mg).

Melting point: 141°–143° C., TLC Rf¹ 0.52

Elemental analysis: as C₃₄H₄₅N₂O₅P Calculated: C: 68.90; H: 7.65; N: 4.73. Found: C: 68.64; H: 7.76; N: 4.50.

IR $\nu_{\max}(\text{KBr})\text{cm}^{-1}$: 1750 (C=O), 1660 (NHC=O), 1500 (Ar), 1200 (P=O)

NMR $\delta_{\text{ppm}}(\text{CDCl}_3)$: 0.81–0.95 (12H, m), 1.36–1.76 (6H, m), 2.00–2.14 (2H, m), 2.83–3.14 (3H, m), 4.80–4.90 (1H, m), 4.60–4.66 (1H, m), 4.86–5.16 (4H, m), 6.75–7.39 (16H, m)

(3) N-(Phenethylphosphonyl)-Leu-Leu.2Na

N-(O-Benzyl-P-phenethylphosphonyl)-Leu-Leu-OBzl (70.0 mg) obtained in (2) was subjected to catalytic reduction in a manner similar to that of Example 1-(3) to obtain powdery N-(phenethylphosphonyl)-Leu-Leu.2Na (51.0 mg).

TLC Rf² 0.58

LSIMS: $m/z=457.1$ [M+H⁺]

EXAMPLE 9

N-(Isoamylphosphonyl)-Leu-Trp.2Na

(1) N-(O-Benzyl-P-Isoamylphosphonyl)-Leu-Trp-OBzl

1,2-Ethanedithiol (0.2 ml) and 8N hydrochloric acid-dioxane (20 ml) were added to Boc-Leu-Trp-OBzl (1.20 g) obtained in Example I-(1) under ice cooling to dissolve it, followed by stirring for 30 minutes. The solvent was removed by distillation under reduced pressure, and diethyl ether was added to the residue to precipitate crystals. The crystals were filtered off and dried. The resulting product was reacted with O-benzyl-P-isoamyl phosphochloridate [prepared from dibenzylisoamyl phosphonate (788 mg) and phosphorus pentachloride (544 mg) by the method described in E. D. Thorsett et al., Proc. Natl. Acad. Sci. USA. 79, 2176 (1982)] in a manner similar to that of Example 1-(2) to obtain needle crystalline colorless N-(O-benzyl-P-isoamylphosphonyl)-Leu-Trp-OBzl (253 mg).

Melting point: 78°–80° C., TLC Rf¹ 0.30

Elemental analysis: as C₃₆H₄₆N₃O₅P Calculated: C: 68.44; H: 7.34; N: 6.65. Found: C: 68.23; H: 7.10; N: 6.61.

IR $\nu_{\max}(\text{KBr})\text{cm}^{-1}$: 1730 (C=O), 1660 (NHC=O), 1530 (Ar), 1200 (P=O)

NMR $\delta_{\text{ppm}}(\text{CDCl}_3)$: 0.80–0.87 (12H, m), 1.31–1.70 (8H, m), 2.73–2.86 (1H, m), 3.23–3.35 (2H, m), 3.71–3.82 (1H, m), 4.65–5.11 (5H, m), 6.76–8.13 (17H, m)

(2) N-(Isoamylphosphonyl)-Leu-Trp.2Na

N-(O-Benzyl-P-isoamylphosphonyl)-Leu-Trp-OBzl (70.0 mg) obtained in (1) was subjected to catalytic reduction in a manner similar to that of Example 1-(3) to obtain powdery N-(isoamylphosphonyl)-Leu-Trp.2Na (54.0 mg).

TLC Rf² 0.58

LSIMS: $m/z=496.1$ [M+H⁺]

EXAMPLE 10

N-(Cyclohexylmethylphosphonyl)-Leu-Trp.2Na

(1) N-(O-Benzyl-P-Cyclohexylmethylphosphonyl)-Leu-Trp-OBzl

1,2-Ethanedithiol (0.2 ml) and 8N hydrochloric acid-dioxane (20 ml) were added to Boc-Leu-Trp-OBzl (1.20 g) obtained in Example 1-(1) under ice cooling to dissolve it, followed by stirring for 30 minutes. The solvent was removed by distillation under reduced pressure, and diethyl

ether was added to the residue to precipitate crystals. The crystals were filtered off and dried. The resulting product was reacted with O-benzyl-P-cyclohexylmethyl phosphochloridate [prepared from dibenzylcyclohexylmethyl phosphonate (1.10 g) and phosphorus pentachloride (767 mg) by the method described in E. D. Thorsett et al., Proc. Natl. Acad. Sci. USA, 79, 2176 (1982)] in a manner similar to that of Example 1-(2) to obtain needle crystalline colorless N-(O-benzyl-P-cyclohexylmethylphosphonyl)-Leu-Trp-OBzl (360 mg).

Melting point: 99°–101° C., TLC Rf¹ 0.32

Elemental analysis: as C₃₈H₄₈N₃O₅P Calculated: C: 69.39; H: 7.36; N: 6.39. Found: C: 69.13; H: 7.42; N: 6.31.

IR v_{max}(KBr)cm⁻¹: 1740 (C=O), 1660 (NHC=O), 1560 (Ar), 1200 (P=O)

NMR δppm(CDCl₃): 0.81–0.88 (6H, m), 0.88–1.99 (16H, m), 2.92–3.05 (1H, m), 3.22–3.35 (2H, m), 3.70–3.80 (1H, m), 4.66–5.10 (5H, m), 6.35–8.31 (17H, m)

(2) N-(Cyclohexylmethylphosphonyl)-Leu-Trp.2Na

N-(O-Benzyl-P-cyclohexylmethylphosphonyl)-Leu-Trp-OBzl (70.0 mg) obtained in (1) was subjected to catalytic reduction in a manner similar to that of Example 1-(3) to obtain powdery N-(cyclohexylmethylphosphonyl)-Leu-Trp.2Na (48.1 mg).

TLC Rf² 0.58

LSIMS: m/z=522.2 [M+H⁺]

EXAMPLE 11

N-(1-Naphthylmethylphosphonyl)-Leu-Trp.2Na

(1) N-[O-Benzyl-P-(1-Naphthyl)methylphosphonyl]-Leu-Trp-OBzl

1,2-Ethanedithiol (0.2 ml) and 8N hydrochloric acid-dioxane (20 ml) were added to Boc-Leu-Trp-OBzl (1.64 g) obtained in Example 1-(1) under ice cooling to dissolve it, followed by stirring for 30 minutes. The solvent was removed by distillation under reduced pressure, and diethyl ether was added to the residue to precipitate crystals. The crystals were filtered off and dried. The resulting product was reacted with O-benzyl-P-(1-naphthyl)methyl phosphochloridate [prepared from dibenzyl 1-naphthylmethyl phosphonate (1.30 g) and phosphorus pentachloride (792 mg) by the method described in E. D. Thorsett et al., Proc. Natl. Acad. Sci. USA, 79, 2176 (1982)] in a manner similar to that of Example 1-(2) to obtain needle crystalline colorless N-[O-benzyl-P-(1-naphthyl)methylphosphonyl]-Leu-Trp-OBzl (560 mg).

Melting point: 54.0°–56.0° C., TLC Rf¹ 0.42

Elemental analysis: as C₄₂H₄₄N₃O₅P Calculated: C: 71.88; H: 6.32; N: 5.99. Found: C: 71.77; H: 6.45; N: 5.95.

IR v_{max}(KBr)cm⁻¹: 1740 (C=O), 1660 (NHC=O), 1510 (Ar), 1210 (P=O)

NMR δppm(CDCl₃): 0.60–0.81 (6H, m), 0.92–1.00 (1H, m), 1.20–1.57 (2H, m), 2.65–2.80 (1H, m), 3.20–3.81 (5H, m), 4.61–5.10 (5H, m), 6.57–8.05 (24H, m)

(2) N-(1-Naphthylmethylphosphonyl)-Leu-Trp.2Na

N-[O-Benzyl-P-(1-naphthyl)methylphosphonyl]-Leu-Trp-OBzl (30.0 mg) obtained in (1) was subjected to catalytic reduction in a manner similar to that of Example 1-(3) to obtain powdery N-(1-naphthylmethylphosphonyl)-Leu-Trp.2Na (17.5 mg).

TLC Rf² 0.62

LSIMS: m/z=566.1 [M+H⁺]

EXAMPLE 12

N-(2-Naphthylmethylphosphonyl)-Leu-Trp.2Na

(1) N-[O-Benzyl-P-(2-Naphthyl)methylphosphonyl]-Leu-Trp-OBzl

1,2-Ethanedithiol (0.2 ml) and 8N hydrochloric acid-dioxane (20 ml) were added to Boc-Leu-Trp-OBzl (1.64 g) obtained in Example 1-(1) under ice cooling to dissolve it, followed by stirring for 30 minutes. The solvent was removed by distillation under reduced pressure, and diethyl ether was added to the residue to precipitate crystals. The crystals were filtered off and dried. The resulting product was reacted with O-benzyl-P-(2-naphthyl)methyl phosphochloridate [prepared from dibenzyl 2-naphthylmethyl phosphonate (1.30 g) and phosphorus pentachloride (792 mg) by the method described in E. D. Thorsett et al., Proc. Natl. Acad. Sci. USA, 79, 2176 (1982)] in a manner similar to that of Example 1-(2) to obtain needle crystalline colorless N-[O-benzyl-P-(2-naphthyl)methylphosphonyl]-Leu-Trp-OBzl (160 mg).

Melting point: 59.0°–61.0° C., TLC Rf¹ 0.45

Elemental analysis: as C₄₂H₄₄N₃O₅P Calculated: C: 71.88; H: 6.32; N: 5.99. Found: C: 71.59; H: 6.38; N: 5.97.

IR v_{max}(KBr)cm⁻¹: 1740 (C=O), 1660 (NHC=O), 1460 (Ar), 1220 (P=O)

NMR δppm(CDCl₃): 0.63–0.81 (6H, m), 1.10–1.29 (1H, m), 1.40–1.50 (1H, m), 1.50–1.63 (1H, m), 2.64–2.76 (1H, m), 3.02–3.30 (4H, m), 3.69–3.80 (1H, m), 4.65–5.10 (5H, m), 6.48–7.97 (24H, m)

(2) N-(2-Naphthylmethylphosphonyl)-Leu-Trp.2Na

N-[O-Benzyl-P-(2-naphthyl)methylphosphonyl]-Leu-Trp-OBzl (50.0 mg) obtained in (1) was subjected to catalytic reduction in a manner similar to that of Example 1-(3) to obtain powdery N-(2-naphthylmethylphosphonyl)-Leu-Trp.2Na (24.5 mg).

TLC Rf² 0.65

LSIMS: m/z=566.1 [M+H⁺]

EXAMPLE 13

N-[2-(1-Naphthyl)ethylphosphonyl]-Leu-Trp.2Na

(1) N-[O-Benzyl-P-[2-(1-Naphthyl)]ethylphosphonyl]-Leu-Trp-OBzl

1,2-Ethanedithiol (0.2 ml) and 8N hydrochloric acid-dioxane (20 ml) were added to Boc-Leu-Trp-OBzl (2.17 g) obtained in Example 1-(1) under ice cooling to dissolve it, followed by stirring for 30 minutes. The solvent was removed by distillation under reduced pressure, and diethyl ether was added to the residue to precipitate crystals. The crystals were filtered off and dried. The resulting product was reacted with O-benzyl-P-[2-(1-naphthyl)]ethyl phosphochloridate [prepared from dibenzyl 2-(1-naphthyl)ethyl phosphonate (1.65 g) and phosphorus pentachloride (1.07 g) by the method described in E. D. Thorsett et al., Proc. Natl. Acad. Sci. USA, 79, 2176 (1982)] in a manner similar to that of Example 1-(2) to obtain needle crystalline colorless N-[O-benzyl-P-[2-(1-naphthyl)]ethylphosphonyl]-Leu-Trp-Bzl (420 mg).

Melting point: 51.5°–54.0° C., TLC Rf¹ 0.28

Elemental analysis: as C₄₃H₄₆N₃O₅P Calculated: C: 72.15; H: 6.48; N: 5.87. Found: C: 72.08; H: 6.40; N: 5.74.

IR v_{max}(KBr)cm⁻¹: 1740 (C=O), 1660 (NHC=O), 1460 (Ar), 1200 (P=O)

NMR δppm(CDCl₃): 0.75–0.90 (6H, m), 1.23–1.39 (1H, m), 1.46–1.71 (2H, m), 1.83–2.00 (1H, m), 2.00–2.13 (1H, m), 2.75–2.83 (1H, m), 3.13–3.38 (4H, m), 3.75–3.87 (1H, m), 4.73–5.60 (5H, m), 6.66–7.97 (24H, m)

(2) N-[2-(1-Naphthyl)ethylphosphonyl]-Leu-Trp.2Na
N-[O-Benzyl-P-[2-(1-naphthyl)ethylphosphonyl]-Leu-Trp-OBzl (50.0 mg) obtained in (1) was subjected to catalytic reduction in a manner similar to that of Example 1-(3) to obtain powdery N-[2-(1-naphthyl)ethylphosphonyl]-Leu-Trp.2Na (31.2 mg).

TLC Rf² 0.63

LSIMS: m/z=580.1 [M+H⁺]

EXAMPLE 14

N-[2-(2-Naphthyl)ethylphosphonyl]-Leu-Trp.2Na

(1) N-[O-Benzyl-P-[2-(2-Naphthyl)ethylphosphonyl]-Leu-Trp-OBzl

1,2-Ethanedithiol (0.2 ml) and 8N hydrochloric acid-dioxane (20 ml) were added to Boc-Leu-Trp-OBzl (2.17 g) obtained in Example 1-(1) under ice cooling to dissolve it, followed by stirring for 30 minutes. The solvent was removed by distillation under reduced pressure, and diethyl ether was added to the residue to precipitate crystals. The crystals were filtered off and dried. The resulting product was reacted with O-benzyl-P-[2-(2-naphthyl)ethyl phosphochloridate [prepared from dibenzyl 2-(2-naphthyl)ethyl phosphonate (1.65 g) and phosphorus pentachloride (1.07 g) by the method described in E. D. Thorsett et al., Proc. Natl. Acad. Sci. USA, 79, 2176 (1982)] in a manner similar to that of Example 1-(2) to obtain needle crystalline colorless N-[O-benzyl-P-[2-(2-naphthyl)ethylphosphonyl]-Leu-Trp-OBzl (850 mg).

Melting point: 51.5°-53.0° C., TLC Rf¹ 0.40

Elemental analysis: as C₄₃H₄₆N₃O₅P Calculated: C: 72.15; H: 6.48; N: 5.87. Found: C: 72.05; H: 6.42; N: 5.79.

IR v_{max}(KBr)cm⁻¹: 1740 (C=O), 1660 (NHC=O), 1510 (Ar), 1200 (P=O)

NMR δppm(CDCl₃): 0.80-0.88 (6H, m), 1.25-1.37 (1H, m), 1.50-1.56 (1H, m), 1.56-1.70 (1H, m), 1.91-2.00 (1H, m), 2.00-2.10 (1H, m), 2.68-2.81 (1H, m), 2.89-3.06 (2H, m), 3.26-3.30 (2H, m), 3.73-3.84 (1H, m), 4.72-5.10 (5H, m), 6.65-7.84 (24H, m)

(2) N-[2-(2-Naphthyl)ethylphosphonyl]-Leu-Trp.2Na


N-[O-Benzyl-P-[2-(2-naphthyl)ethylphosphonyl]-Leu-Trp-OBzl (50.0 mg) obtained in (1) was subjected to catalytic reduction in a manner similar to that of Example 1-(3) to obtain powdery N-[2-(2-naphthyl)ethylphosphonyl]-Leu-Trp.2Na (26.1 mg).

TLC Rf² 0.66

LSIMS: m/z=580.1 [M+H⁺]

What is claimed is:

1. A compound represented by formula [I] or a pharmaceutically acceptable salt thereof:



wherein

R₁ is C₁₋₁₂ alkyl group which may be substituted by C₃₋₈ cycloalkyl, halogen, hydroxy which may be protected, C₁₋₂ alkoxy, ketone or amino which may be protected, (ii) a 5 to 7 member cycloalkyl group which may be substituted by lower alkyl having 1 to 3 carbon atoms, halogen, hydroxy which may be protected, C₁₋₂ alkoxy, keto, or amino which may be protected or (iii) an aralkyl group which may be substituted by lower alkyl having 1 to 3 carbon atoms, C₅₋₆ cycloalkyl, halogen, hydroxy which may be protected, or C₁₋₂ alkoxy;

R₂ is (i) a C₁₋₈ alkyl group (ii) a cyclohexylmethylene group or (iii) a benzyl group; and


R₃ is [an indolylmethyl group or] a benzyl group, *except compounds in which (i) R₂ is a methyl group and (ii) R₁ is benzyloxycarbonylaminoethyl, R₂ is isobutyl and R₃ is benzyl.*

2. The compound according to claim 1, in which R₁ is selected from the group which consists of an alkyl group having 1 to 12 carbon atoms; a 5-, 6- or 7-membered alicyclic alkyl group; and an alkyl group having 1 to 5 carbon atoms substituted by an aromatic hydrocarbon group having 6 to 12 carbon atoms.

3. The compound according to claim 2, in which said alkyl group having 1 to 12 carbon atoms is isoamyl or cyclohexylmethyl, and said alkyl group having 1 to 5 carbon atoms substituted by the aromatic hydrocarbon group is phenylethyl naphthylmethyl or naphthylethyl.

[4. The compound according to claim 1, in which said indolylmethyl group is indol-3-ylmethyl.]

5. A compound represented by formula [I] or a pharmaceutically acceptable salt thereof:



wherein R₁ is isoamyl, cyclohexylmethyl, phenethyl, naphthylmethyl or naphthylethyl R₂ is isobutyl or benzyl, and R₃ is indol-3-ylmethyl.

6. The compound according to claim 5, in which said compound is N-(phenethylphosphonyl)-leucyl-tryptophan.

7. The compound according to claim 5, in which said compound is N-(cyclohexylmethylphosphonyl)-leucyl-tryptophan.

8. The compound according to claim 5, in which said compound is N-(1-naphthylmethylphosphonyl)-leucyl-tryptophan.


9. The compound according to claim 5, in which said compound is N-{2-(1-naphthyl)ethylphosphonyl}-leucyl-tryptophan.

10. The compound according to claim 5, in which said compound is N-{2-(2-naphthyl)ethylphosphonyl}-leucyl-tryptophan.

11. A pharmaceutical composition comprising the compound or the pharmaceutically acceptable salt thereof claimed in claim 5 and a pharmaceutically acceptable carrier.

12. A method for bringing about endothelin-converting enzyme inhibiting activity in a warm-blood animal, which comprises administering an effective amount of the compound or the pharmaceutically acceptable salt thereof claimed in claim 5 to the warm-blood animal.

13. A compound represented by formula [I] or a pharmaceutically acceptable salt thereof:



wherein


R₁ is (i) a C₁₋₁₂ alkyl group which may be substituted by C₃₋₈ cycloalkyl, halogen, hydroxy which may be protected, C₁₋₂ alkoxy, or amino which may be protected, (ii) a 5 to 7 member cycloalkyl group which may be substituted by lower alkyl having 1 to 3 carbon atoms, halogen, hydroxy which may be protected, C₁₋₂

alkoxy, keto, or amino which may be protected, or (iii) a C₇₋₁₇ aralkyl group which may be substituted by lower alkyl having 1 to 3 carbon atoms, C₅₋₆ cycloalkyl, halogen, hydroxy which may be protected, or C₁₋₂ alkoxy;

R₂ is (i) a C₁₋₈ alkyl group, (ii) a 5 to 7 member cycloalkyl group, or (iii) a benzyl group; and


R₃ is a C₁₋₈ alkyl group which is substituted by 3-indolyl, except compounds in which R₂ is a methyl group.

14. A compound represented by formula [I] or a pharmaceutically acceptable salt thereof:



wherein R₁ is phenethyl, isoamyl, cyclohexylmethyl naphthylmethyl or naphthylethyl, R₂ is propyl, butyl, cyclohexylmethyl or benzyl and R₃ is benzyl or indolylmethyl.

15. A compound represented by formula [I] or a pharmaceutically acceptable salt thereof:



wherein

R₁ is an alkyl group of 1 to 12 carbon atoms or an alkyl group having 1 to 5 carbon atoms substituted by an aromatic hydrocarbon group having 6 to 12 carbon atoms;

R₂ is an alkyl group having 1 to 8 carbon atoms; an alkyl group having 1 to 8 carbon atoms substituted by a cycloalkyl group having 5 to 7 carbon atoms; or an alkyl group having 1 to 5 carbon atoms substituted by an aromatic hydrocarbon group having 6 to 12 carbon atoms; and

R₃ is alkyl having 1 to 8 carbon atoms substituted by indolyl or an aromatic hydrocarbon group having [to] 6 to 12 carbon atoms, except compounds in which R₂ is a methyl group.

16. The compound of claim 15 wherein R₁ is isoamyl, cyclohexylmethyl, phenylethyl, naphthylmethyl or naphthylethyl; R₂ is isobutyl or benzyl, and R₃ is indolylmethyl or benzyl.

17. The compound according to claim 1, in which R₂ is *n*-propyl, isopropyl, isobutyl, *sec*-butyl, cyclohexylmethyl or benzyl.

18. A method for bringing about endothelin-converting enzyme inhibiting activity in a warm-blood animal, which comprises administering an effective amount of the compound or the pharmaceutically acceptable salt thereof claimed in claim 1 to the warm-blood animal.

19. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the compound of claim 1 or a pharmaceutically acceptable salt thereof.

20. The compound according to claim 13, in which R₂ is (i) a C₃₋₈ alkyl group, (ii) a 5 to 7 member cycloalkyl group, or (iii) a benzyl group.

21. The compound according to claim 13, in which R₂ is *n*-propyl, isopropyl, isobutyl, *sec*-butyl, cyclohexylmethyl or benzyl.

22. A method for bringing about endothelin-converting enzyme inhibiting activity in a warm-blooded animal, which comprises administering an effective amount of the compound or the pharmaceutically acceptable salt thereof claimed in claim 13 to the warm-blooded animal.

23. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the compound of claim 13 or a pharmaceutically acceptable salt thereof.

24. The compound according to claim 14, in which R₃ is indolylmethyl.

25. The compound according to claim 15, in which R₂ is an alkyl group having 3 to 8 carbon atoms; an alkyl group having 1 to 8 carbon atoms substituted by a cycloalkyl group having 5 to 7 carbon atoms; or an alkyl group having 1 to 5 carbon atoms substituted by an aromatic hydrocarbon group having 6 to 12 carbon atoms; and R₃ is alkyl having 1 to 8 carbon atoms substituted by indolyl.


26. The compound according to claim 15, in which R₂ is *n*-propyl, isopropyl, isobutyl, *sec*-butyl, cyclohexylmethyl or benzyl.

27. A method for bringing about endothelin-converting enzyme inhibiting activity in a warm-blooded animal, which comprises administering an effective amount of the compound or the pharmaceutically acceptable salt thereof claimed in claim 15 to the warm-blooded animal.

28. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the compound of claim 15 or a pharmaceutically acceptable salt thereof.

29. The compound of claim 16 wherein R₃ is indolylmethyl.

30. A compound represented by formula [I] or a pharmaceutically acceptable salt thereof:



wherein:

R₁ is (i) a C₁₋₁₂ alkyl group which may be substituted by C₃₋₈ cycloalkyl, halogen, hydroxy which may be protected, C₁₋₂ alkoxy, ketone or amino which may be protected, (ii) a 5 to 7 member cycloalkyl group which may be substituted by lower alkyl having 1 to 3 carbon atoms, halogen, hydroxy which may be protected, C₁₋₂ alkoxy, keto, or amino which may be protected or (iii) an aralkyl group which may be substituted by lower alkyl having 1 to 3 carbon atoms, C₅₋₆ cycloalkyl, halogen, hydroxy which may be protected, or C₁₋₂ alkoxy;

R₂ is (i) a C₁₋₈ alkyl group (ii) a cyclohexylmethylene group or (iii) benzyl group and

R₃ is an indolylmethyl group, except compounds in which R₂ is a methyl group.

31. The compound according to claim 30, in which R₁ is selected from the group which consists of an alkyl group having 1 to 12 carbon atoms; a 5-, 6- or 7-membered alicyclic alkyl group; and an alkyl group having 1 to 5 carbon atoms substituted by an aromatic hydrocarbon group having 6 to 12 carbon atoms.

32. The compound according to claim 31, in which said alkyl group having 1 to 12 carbon atoms is isoamyl or cyclohexylmethyl, and said alkyl group having 1 to 5 carbon atoms substituted by the aromatic hydrocarbon group is phenylethyl, naphthylmethyl or naphthylethyl.


33. The compound according to claim 30, in which said indolylmethyl group is indol-3-ylmethyl.

34. The compound according to claim 30, in which R₂ is (i) a C₃₋₈ alkyl group, (ii) a cyclohexylmethylene group or (iii) a benzyl group; and R₃ is an indolylmethyl group.

35. A method for bringing about endothelin-converting enzyme inhibiting activity in a warm-blooded animal, which comprises administering an effective amount of the compound or the pharmaceutically acceptable salt thereof claimed in claim 30 to the warm-blooded animal.

36. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the compound of claim 30 or a pharmaceutically acceptable salt thereof.

37. A method for bringing about endothelin-converting enzyme inhibiting activity in a warm-blooded animal, which comprises administering to the animal an effective amount of a compound represented by the formula [I] or a pharmaceutically acceptable salt thereof:



[I] 15

wherein:

R_1 is (i) a C_{1-8} alkyl group which may be substituted by C_{5-8} cycloalkyl, halogen, hydroxy which may be protected, C_{1-2} alkoxy, keto or amino which may be protected, (ii) a 5 to 7 member cycloalkyl group which may be substituted by lower alkyl having 1 to 3 carbon atoms, halogen, hydroxy which may be protected C_{1-2} alkoxy, keto, or amino which may be protected or (iii) an aralkyl group which may be substituted by lower alkyl having 1 to 3 carbon atoms, C_{5-6} cycloalkyl, halogen, hydroxy which may be protected, or C_{1-2} alkoxy;

R_2 is (i) a C_{1-8} alkyl group (ii) a cyclohexylmethyl group or (iii) a benzyl group; and

R_3 is an indolylmethyl group or a benzyl group; except compounds in which (i) R_2 is a methyl group and (ii) R_1 is benzyloxycarbonylaminoethyl, R_2 is isobutyl and R_3 is benzyl.

* * * * *